DK2363488T3 - Postweaning multisystemisk wasting syndrom-virus fra grise - Google Patents
Postweaning multisystemisk wasting syndrom-virus fra grise Download PDFInfo
- Publication number
- DK2363488T3 DK2363488T3 DK10012196.1T DK10012196T DK2363488T3 DK 2363488 T3 DK2363488 T3 DK 2363488T3 DK 10012196 T DK10012196 T DK 10012196T DK 2363488 T3 DK2363488 T3 DK 2363488T3
- Authority
- DK
- Denmark
- Prior art keywords
- pcvii
- polypeptide
- leu
- arg
- pro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10041—Use of virus, viral particle or viral elements as a vector
- C12N2750/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (13)
1. Isoleret immunogenisk porcin circovirus Type II (PCVII)-polypeptid omfattende: (a) MPSKKNGRSG PQPHKRWVFT LNNPSEDERK KIRELPISLF DYFIVGEEGN EEGRTPHLQG FANFVKKQTF NKVKWYLGAR CHIEKAKGTD QQNKEYCSKE GNLLIECGAP RSQGQRSDLS TAVSTLLESG ILVTVAKQHP VTFVKNFRGL AELLKVSGKM QKRDWKTNVH FIVGPPGCGK SKWAANFANP ETTYWKPPKN KWWDGYHGEK VVVIDDFYGW LPWDDLLRLC DRYPLTVKTK GGTVPFLARS ILITSNQTPL EWYSSTAVPA VEALYRRITS LVFWKNATKQ STEEGGQFVT LSPPCPEFPY EINY (ORF1); eller (b) polypeptid afledt fra ORF1 med mindst 98% identitet med den fulde længde af ORF1; eller (c) polypeptid afledt fra ORF1 med mindst 90% identitet med den fulde længde af ORF1; hvor polypeptidet ikke er MPSKKNGRSGPQPHKRWVFTLNNPSEDERKKIRDLPISLFDYFIVGEEGNEEGRTPHLQG FANFVKKQTFNKVKWYLGARCHIEKAKGTDQQNKEYCSKEGNLLMECGAPRSQGQRSDLS TAVSTLLESGSLVTVAEQHPVTFVRNFRGLAELLKVSGKMQKRDWKTNVHVIVGPPGCGK SKWAANFADPETTYWKPPRNKWWDGYHGEEVWIDDFYGWLPWDDLLRLCDRYPLTVETK GGTVPFLARSILITSNQTPLEWYSSTAVPAVEALYRRITSLVFWKNATEQSTEEGGQFVT LSPPCPEFPYEINY, eller MPSKKNGRSGPQPHKRWVFTLNNPSEDERKKIRELPISLFDYFIVGEEGXEEXRTPHLQG FANFVKKQTFNKVKWYLGARCHIEKAKGTDQQNKEYCSKEGNLLIECGAPRSQGQRSDLS TAVSTLLESGSLVTVAEQHPVTFVRNFRGLAELLKVSGKMQKRDWKTNVHVIVGPPGCGK SKWAANFADPETTYWKPPRNKWWDGYHGEEVWIDDFYGWLPWDDLLRLCDRYPLTVETK GGTVXXXARSILITSNQTPLEWYSSTAVPAVEALYRRITSLVFWKNATEQSTEEGGQXVT LSPPCPEFPYEINY; eller (d) fusionsprotein omfattende et hvilket som helst af (a) til (c).
2. Isoleret polypeptid ifølge krav 1, hvor polypeptidet er genereret ved kemisk syntese.
3. Isoleret polypeptid ifølge et hvilket som helst af kravene 1 til 2, hvor polypeptidet er genereret ved rekombinant produktion.
4. Isoleret polypeptid ifølge krav 3, hvor polypeptidet udtrykkes under anvendelse af baculovirus.
5. Rekombinant vektor omfattende et polynukleotid der koder for et immunogent PCVII-polypeptid som beskrevet i et hvilket som helst af kravene 1 til 4.
6. Rekombinant vektor ifølge krav 5, hvor den rekombinante vektor omfatter et polynukleotid der koder for det immunogene polypeptid MPSKKNGRSG PQPHKRWVFT LNNPSEDERK KIRELPISLF DYFIVGEEGN EEGRTPHLQG FANFVKKQTF NKVKWYLGAR CHIEKAKGTD QQNKEYCSKE GNLLIECGAP RSQGQRSDLS TAVSTLLESG ILVTVAKQHP VTFVKNFRGL AELLKVSGKM QKRDWKTNVH FIVGPPGCGK SKWAANFANP ETTYWKPPKN KWWDGYHGEK VVVIDDFYGW LPWDDLLRLC DRYPLTVKTK GGTVPFLARS ILITSNQTPL EWYSSTAVPA VEALYRRITS LVFWKNATKQ STEEGGQFVT LSPPCPEFPY EINY (ORF1).
7. Rekombinant værtscelle transformeret med vektoren ifølge krav 5 eller 6.
8. Rekombinant værtscelle ifølge krav 7, hvor den rekombinante værtscelle er en pattedyrcelle.
9. Rekombinant værtscelle ifølge krav 7, hvor den rekombinante værtscelle er en bakteriecelle.
10. Rekombinant værtscelle ifølge krav 7, hvor den rekombinante værtscelle er en gærcelle.
11. Rekombinant værtscelle ifølge krav 7, hvor den rekombinante værtscelle er en insektcelle.
12. Sammensætning omfattende et immunogent PCVII-polypeptid og en farmaceutisk eller veterinært acceptabel vehikel; hvor det immunogene PCVII-polypeptid omfatter: (a) MPSKKNGRSG PQPHKRWVFT LNNPSEDERK KIRELPISLF DYFIVGEEGN EEGRTPHLQG FANFVKKQTF NKVKWYLGAR CHIEKAKGTD QQNKEYCSKE GNLLIECGAP RSQGQRSDLS TAVSTLLESG ILVTVAKQHP VTFVKNFRGL AELLKVSGKM QKRDWKTNVH FIVGPPGCGK SKWAANFANP ETTYWKPPKN KWWDGYHGEK VVVIDDFYGW LPWDDLLRLC DRYPLTVKTK GGTVPFLARS ILITSNQTPL EWYSSTAVPA VEALYRRITS LVFWKNATKQ STEEGGQFVT LSPPCPEFPY EINY (ORF1); eller (b) polypeptid afledt fra ORF1 med mindst 98% identitet med den fulde længde af ORF1; eller (c) polypeptid afledt fra ORF1 med mindst 90% identitet med den fulde længde af ORF1; hvor polypeptidet ikke er MPSKKNGRSGPQPHKRWVFTLNNPSEDERKKIRDLPISLFDYFIVGEEGNEEGRTPHLQG FANFVKKQTFNKVKWYLGARCHIEKAKGTDQQNKEYCSKEGNLLMECGAPRSQGQRSDLS TAVSTLLESGSLVTVAEQHPVTFVRNFRGLAELLKVSGKMQKRDWKTNVHVIVGPPGCGK SKWAANFADPETTYWKPPRNKWWDGYHGEEVWIDDFYGWLPWDDLLRLCDRYPLTVETK GGTVPFLARSILITSNQTPLEWYSSTAVPAVEALYRRITSLVFWKNATEQSTEEGGQFVT LSPPCPEFPYEINY, eller MPSKKNGRSGPQPHKRWVFTLNNPSEDERKKIRELPISLFDYFIVGEEGXEEXRTPHLQG FANFVKKQTFNKVKWYLGARCHIEKAKGTDQQNKEYCSKEGNLLIECGAPRSQGQRSDLS TAVSTLLESGSLVTVAEQHPVTFVRNFRGLAELLKVSGKMQKRDWKTNVHVIVGPPGCGK SKWAANFADPETTYWKPPRNKWWDGYHGEEWVIDDFYGWLPWDDLLRLCDRYPLTVETK GGTVXXXARSILITSNQTPLEWYSSTAVPAVEALYRRITSLVFWKNATEQSTEEGGQXVT LSPPCPEFPYEINY? eller (d) fusionsprotein omfattende et hvilket som helst af (a) til (c).
13. Sammensætningen ifølge krav 12, yderligere omfattende en adjuvans.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6923397P | 1997-12-11 | 1997-12-11 | |
| US6975097P | 1997-12-16 | 1997-12-16 | |
| EP07008633.5A EP1816200B1 (en) | 1997-12-11 | 1998-12-11 | Postweaning multisystemic wasting syndrome virus for pigs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2363488T3 true DK2363488T3 (da) | 2014-11-24 |
Family
ID=26749812
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10012196.1T DK2363488T3 (da) | 1997-12-11 | 1998-12-11 | Postweaning multisystemisk wasting syndrom-virus fra grise |
| DK98959682T DK1037909T3 (da) | 1997-12-11 | 1998-12-11 | Postweaning multisystemisk wasting-syndromvirus (PMWS) fra svin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98959682T DK1037909T3 (da) | 1997-12-11 | 1998-12-11 | Postweaning multisystemisk wasting-syndromvirus (PMWS) fra svin |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20020106639A1 (da) |
| EP (2) | EP2363488B1 (da) |
| JP (5) | JP3795751B2 (da) |
| KR (3) | KR100879650B1 (da) |
| CN (1) | CN1309708A (da) |
| AT (1) | ATE364624T1 (da) |
| AU (1) | AU764379B2 (da) |
| BR (1) | BR9813485A (da) |
| CA (1) | CA2313806A1 (da) |
| CY (1) | CY1107720T1 (da) |
| DE (2) | DE07008633T1 (da) |
| DK (2) | DK2363488T3 (da) |
| ES (2) | ES2526760T3 (da) |
| ID (1) | ID28224A (da) |
| NZ (1) | NZ505008A (da) |
| PT (2) | PT2363488E (da) |
| RU (1) | RU2000118777A (da) |
| WO (1) | WO1999029717A2 (da) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
| US7211379B2 (en) | 1997-10-03 | 2007-05-01 | Merial Sas | Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 |
| UA78180C2 (uk) * | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
| US7192594B2 (en) | 1997-10-03 | 2007-03-20 | Merial Limited | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
| US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
| US20040062775A1 (en) * | 1997-12-05 | 2004-04-01 | Agence Francaise De Securite Sanitaire Des Aliments | Circovirus sequences associated with piglet weight loss disease (PWD) |
| FR2772047B1 (fr) * | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
| JP3795751B2 (ja) * | 1997-12-11 | 2006-07-12 | ユニバーシティ オブ サスカッチェワン | ブタからの離乳後多全身系消耗症候群ウイルス |
| EP1816200B1 (en) | 1997-12-11 | 2016-03-09 | Merial | Postweaning multisystemic wasting syndrome virus for pigs |
| US6943152B1 (en) * | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
| ES2170622B1 (es) * | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
| JP2004503234A (ja) * | 2000-06-15 | 2004-02-05 | パーデュー・リサーチ・ファウンデーション | ブタの先天性振せん用ワクチン |
| US7276353B2 (en) * | 2001-12-12 | 2007-10-02 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
| ATE489965T1 (de) | 2004-09-09 | 2010-12-15 | Novartis Vaccines & Diagnostic | Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen |
| US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
| UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
| HUE025537T2 (en) | 2004-12-30 | 2016-05-30 | Boehringer Ingelheim Vetmedica Inc | PCV2-immunogenic compositions and methods for preparing such compositions |
| US7833707B2 (en) | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
| US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
| WO2006132598A1 (en) * | 2005-06-07 | 2006-12-14 | Temasek Life Sciences Laboratory Limited | Porcine circovirus type 2 vaccines |
| EP1968630B1 (en) | 2005-12-29 | 2018-01-24 | Boehringer Ingelheim Vetmedica, Inc. | Multivalent pcv2 immunogenic compositions |
| MX338626B (es) | 2005-12-29 | 2016-04-26 | Boehringer Ingelheim Vetmed | Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos. |
| US8053191B2 (en) | 2006-08-31 | 2011-11-08 | Westend Asset Clearinghouse Company, Llc | Iterative nucleic acid assembly using activation of vector-encoded traits |
| EP2859900A1 (en) * | 2006-12-11 | 2015-04-15 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
| JP5200223B2 (ja) | 2006-12-15 | 2013-06-05 | ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド | Pcv2抗原によるブタの処置 |
| EP1941903A1 (en) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
| EP1958644A1 (en) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
| CN101294223B (zh) * | 2007-05-08 | 2011-04-06 | 深圳太太基因工程有限公司 | 一种用于检测ⅱ型猪圆环病毒核苷酸片段的引物和探针序列 |
| US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
| WO2009088950A2 (en) * | 2007-12-31 | 2009-07-16 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 orf2 virus like particle with foreign amino acid insertion |
| KR20100113582A (ko) * | 2008-01-23 | 2010-10-21 | 베링거잉겔하임베트메디카인코퍼레이티드 | Pcv2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법 |
| US20110033495A1 (en) * | 2008-02-15 | 2011-02-10 | Boehringer Ingelheim Vetmedica, Inc. | Methods and compositions for reducing the impact of enteric diseases |
| KR100983873B1 (ko) * | 2008-07-04 | 2010-10-01 | 대한민국 | 돼지 써코바이러스 타입 1 및 2의 감별진단을 위한미니어레이법 |
| US8703468B2 (en) | 2008-11-28 | 2014-04-22 | Ceva Sante Animale | Porcine circovirus type 2B isolate and uses thereof |
| AR078253A1 (es) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
| US10207240B2 (en) | 2009-11-03 | 2019-02-19 | Gen9, Inc. | Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly |
| WO2011066185A1 (en) | 2009-11-25 | 2011-06-03 | Gen9, Inc. | Microfluidic devices and methods for gene synthesis |
| EP3597771A1 (en) | 2009-11-25 | 2020-01-22 | Gen9, Inc. | Methods and apparatuses for chip-based dna error reduction |
| WO2011085075A2 (en) | 2010-01-07 | 2011-07-14 | Gen9, Inc. | Assembly of high fidelity polynucleotides |
| CA2804604C (en) * | 2010-07-08 | 2023-10-03 | United Biomedical, Inc. | Designer peptide-based pcv2 vaccine |
| CN103502448B (zh) | 2010-11-12 | 2017-03-29 | Gen9股份有限公司 | 核酸合成的方法和设备 |
| WO2012064975A1 (en) | 2010-11-12 | 2012-05-18 | Gen9, Inc. | Protein arrays and methods of using and making the same |
| LT2944693T (lt) | 2011-08-26 | 2019-08-26 | Gen9, Inc. | Kompozicijos ir būdai, skirti nukleorūgščių didelio tikslumo sąrankai |
| HUP1100470A2 (en) * | 2011-08-30 | 2013-03-28 | Mezoegazdasagi Biotechnologiai Kutatokoezpont | Nanoparticle-based veterinary vaccine |
| US9150853B2 (en) | 2012-03-21 | 2015-10-06 | Gen9, Inc. | Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis |
| CA2871505C (en) | 2012-04-24 | 2021-10-12 | Gen9, Inc. | Methods for sorting nucleic acids and multiplexed preparative in vitro cloning |
| IL236303B (en) | 2012-06-25 | 2022-07-01 | Gen9 Inc | Methods for high-throughput nucleic acid assembly and sequencing |
| WO2014153168A2 (en) * | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Porcine astrovirus sequences and uses thereof |
| EP3049106A1 (en) | 2013-09-25 | 2016-08-03 | Zoetis Services LLC | Pcv2b divergent vaccine composition and methods of use |
| US9505808B2 (en) | 2013-10-02 | 2016-11-29 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 ORF2 protein variant and virus like particles composed thereof |
| CN103834670B (zh) * | 2014-02-24 | 2016-01-06 | 福州大北农生物技术有限公司 | 优化的猪圆环病毒orf2截短基因 |
| CN104593526B (zh) * | 2015-02-05 | 2017-10-27 | 兰州生物制品研究所有限责任公司 | 一种用于猪圆环病毒检测的方法及引物组 |
| HK1252427A1 (zh) | 2015-05-14 | 2019-05-24 | Boehringer Ingelheim Animal Health USA Inc. | 猪环状病毒生产方法和pcv2疫苗 |
| EP3254692A1 (en) | 2016-06-10 | 2017-12-13 | Ceva Sante Animale | Multivalent recombinant spv |
| CN119488586A (zh) | 2018-03-26 | 2025-02-21 | 勃林格殷格翰动物保健美国有限公司 | 制备免疫原性组合物的方法 |
| CN109021115B (zh) * | 2018-08-06 | 2021-05-04 | 青岛明勤生物科技有限公司 | 一种猪圆环病毒三价亚单位疫苗 |
| KR102211502B1 (ko) * | 2019-08-12 | 2021-02-03 | 최영준 | 원적외선 원료를 활용한 피부접착용 패치 |
| CN113322350B (zh) * | 2021-05-06 | 2022-04-08 | 深圳海关动植物检验检疫技术中心 | 一种同时检测猪圆环病毒2型和猪圆环病毒3型病毒的试剂盒及应用 |
| CN121463956A (zh) | 2023-05-03 | 2026-02-03 | 勃林格殷格翰动物保健有限公司 | 诱导免疫应答的方法 |
| EP4704977A1 (en) | 2023-05-03 | 2026-03-11 | Boehringer Ingelheim Vetmedica GmbH | Immunogenic composition useful for self-administration by pigs |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4491632A (en) | 1979-10-22 | 1985-01-01 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
| US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
| US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| EP0043718B1 (en) | 1980-07-07 | 1984-11-28 | National Research Development Corporation | Improvements in or relating to cell lines |
| US4341761A (en) | 1980-07-25 | 1982-07-27 | E. I. Du Pont De Nemours And Company | Antibodies to immunogenic peptides and their use to purify human fibroblast interferon |
| US4466917A (en) | 1981-02-12 | 1984-08-21 | New York University | Malaria vaccine |
| US4493890A (en) | 1981-03-23 | 1985-01-15 | Miles Laboratories, Inc. | Activated apoglucose oxidase and its use in specific binding assays |
| JPS5873993U (ja) | 1981-11-12 | 1983-05-19 | 三菱電機株式会社 | 2気筒回転式圧縮機 |
| US4399121A (en) | 1981-11-04 | 1983-08-16 | Miles Laboratories, Inc. | Iodothyronine immunogens and antibodies |
| US4427783A (en) | 1981-12-14 | 1984-01-24 | Hoffmann-La Roche Inc. | Immunoassay of thymosin α1 |
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| GB8306426D0 (en) | 1983-03-09 | 1983-04-13 | Malcolm A D B | Detecting polynucleotide sequence |
| US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| EP0204510B1 (en) | 1985-05-31 | 1991-07-10 | Amoco Corporation | Amplification of hybridization signals by employing complementary dna strands |
| US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| SU1538305A1 (ru) | 1987-07-21 | 1994-12-15 | Всесоюзный государственный научно-контрольный институт ветеринарных препаратов Госагропрома СССР | Ассоциированная вакцина против лептоспироза и парвовирусной инфекции свиней |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| CA2489769A1 (en) | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5800992A (en) * | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| ES2026827A6 (es) * | 1991-03-26 | 1992-05-01 | Ercros Sa | Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino. |
| NZ309172A (en) * | 1995-06-07 | 1999-11-29 | Leadd B | Neutralizing conformational epitopes of chicken anemia virus |
| FR2751224B1 (fr) * | 1996-07-19 | 1998-11-20 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs |
| US6391314B1 (en) * | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
| FR2781159B1 (fr) * | 1998-07-06 | 2000-10-06 | Merial Sas | Vaccin circovirus et parvovirus porcin |
| UA78180C2 (uk) * | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
| FR2769321B1 (fr) | 1997-10-03 | 2001-10-26 | Merial Sas | Nouveaux circovirus porcins, vaccins et reactifs de diagnostics |
| US20060029617A1 (en) * | 1997-10-03 | 2006-02-09 | Charreyre Catherine E | Porcine circovirus and Helicobacter combination vaccines and methods of use |
| FR2772047B1 (fr) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
| JP3795751B2 (ja) * | 1997-12-11 | 2006-07-12 | ユニバーシティ オブ サスカッチェワン | ブタからの離乳後多全身系消耗症候群ウイルス |
| US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
| WO2008151215A1 (en) * | 2007-06-04 | 2008-12-11 | Merial Limited | Production of porcine circovirus proteins in plants |
-
1998
- 1998-12-11 JP JP2000524308A patent/JP3795751B2/ja not_active Expired - Lifetime
- 1998-12-11 EP EP10012196.1A patent/EP2363488B1/en not_active Expired - Lifetime
- 1998-12-11 KR KR1020077022457A patent/KR100879650B1/ko not_active Expired - Lifetime
- 1998-12-11 PT PT100121961T patent/PT2363488E/pt unknown
- 1998-12-11 BR BR9813485-0A patent/BR9813485A/pt not_active Application Discontinuation
- 1998-12-11 ES ES10012196.1T patent/ES2526760T3/es not_active Expired - Lifetime
- 1998-12-11 KR KR1020067012973A patent/KR20060088908A/ko not_active Ceased
- 1998-12-11 EP EP98959682A patent/EP1037909B1/en not_active Expired - Lifetime
- 1998-12-11 DE DE07008633T patent/DE07008633T1/de active Pending
- 1998-12-11 ID IDW20001094D patent/ID28224A/id unknown
- 1998-12-11 CA CA002313806A patent/CA2313806A1/en not_active Abandoned
- 1998-12-11 WO PCT/CA1998/001130 patent/WO1999029717A2/en not_active Ceased
- 1998-12-11 PT PT98959682T patent/PT1037909E/pt unknown
- 1998-12-11 KR KR1020007006378A patent/KR100688008B1/ko not_active Expired - Lifetime
- 1998-12-11 DK DK10012196.1T patent/DK2363488T3/da active
- 1998-12-11 CN CN98813431A patent/CN1309708A/zh active Pending
- 1998-12-11 ES ES98959682T patent/ES2289796T3/es not_active Expired - Lifetime
- 1998-12-11 RU RU2000118777/13A patent/RU2000118777A/ru not_active Application Discontinuation
- 1998-12-11 AT AT98959682T patent/ATE364624T1/de active
- 1998-12-11 DE DE69837934T patent/DE69837934T2/de not_active Expired - Lifetime
- 1998-12-11 DK DK98959682T patent/DK1037909T3/da active
- 1998-12-11 NZ NZ505008A patent/NZ505008A/en not_active IP Right Cessation
- 1998-12-11 AU AU15526/99A patent/AU764379B2/en not_active Expired
-
2001
- 2001-08-20 US US09/935,428 patent/US20020106639A1/en not_active Abandoned
-
2002
- 2002-12-31 US US10/334,245 patent/US7144698B2/en not_active Expired - Lifetime
-
2006
- 2006-01-25 JP JP2006016175A patent/JP2006187289A/ja active Pending
- 2006-06-26 US US11/474,609 patent/US7741039B2/en not_active Expired - Lifetime
-
2007
- 2007-08-23 CY CY20071101098T patent/CY1107720T1/el unknown
-
2010
- 2010-06-02 JP JP2010126526A patent/JP5504056B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-28 JP JP2013069652A patent/JP2013188211A/ja not_active Withdrawn
-
2014
- 2014-02-03 JP JP2014018298A patent/JP5848376B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2363488T3 (da) | Postweaning multisystemisk wasting syndrom-virus fra grise | |
| US7803926B2 (en) | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs | |
| EP1871884A2 (en) | Porcine circovirus and helicobacter combination vaccines | |
| EP1816200B1 (en) | Postweaning multisystemic wasting syndrome virus for pigs | |
| AU2003248395B2 (en) | Porcine CircoViruses, vaccines and diagnostic reagents | |
| AU2006202480B2 (en) | Porcine circo viruses, vaccines and diagnostic reagents I | |
| HK1102829B (en) | Postweaning multisystemic wasting syndrome virus for pigs | |
| MXPA00005561A (es) | Virus del sindrome de emaciacion multisistematica post-destete de cerdos |